SciSparc Ltd. announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office (the "Patent"). The Patent aligns seamlessly with the Company's proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. This patent grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc's technologies.

The Patent covers the compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant. The Patent was granted on account of the unique composition of cannabinoids and n-acylthanolamines and the methods for their use in preventing and treating a variety of cannabinoid-treated conditions.